Compare UDMY & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDMY | KALV |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 693.7M | 757.7M |
| IPO Year | 2021 | 2014 |
| Metric | UDMY | KALV |
|---|---|---|
| Price | $4.64 | $17.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $9.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 1.5M | 761.7K |
| Earning Date | 04-29-2026 | 05-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.36 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $789,844,000.00 | $50,000,000.00 |
| Revenue This Year | $4.12 | N/A |
| Revenue Next Year | $4.54 | N/A |
| P/E Ratio | $158.17 | ★ N/A |
| Revenue Growth | 0.42 | ★ 495.66 |
| 52 Week Low | $4.35 | $9.83 |
| 52 Week High | $8.92 | $19.00 |
| Indicator | UDMY | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 56.35 |
| Support Level | $4.35 | $14.59 |
| Resistance Level | $5.38 | $17.30 |
| Average True Range (ATR) | 0.22 | 1.10 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 14.94 | 57.48 |
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Enterprise segment and Consumer segment, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America, and also has its presence in Europe, Middle East, Africa; Asia Pacific; and Latin America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.